Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31297829)

  • 1. Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.
    Stuart E; Banerjee S; de la Torre J; Wang Y; Scherzer N; Burgoyne AM; Parry L; Fanta PT; Ramamoorthy S; Sicklick JK
    J Surg Oncol; 2019 Sep; 120(4):715-721. PubMed ID: 31297829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
    Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
    Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
    Wu X; Li J; Xu W; Gao J; Li Y; Shen L
    Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.
    Yang W; Liu Q; Lin G; Zhang B; Cao H; Zhao Y; Xia L; Feng F; Xiong Z; Hu J; Ye Y; Tao K; Zhang P
    J Surg Oncol; 2021 Dec; 124(7):1128-1135. PubMed ID: 34324197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of outcomes between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis.
    Ling JY; Ding MM; Yang ZF; Zhao YD; Xie XY; Shi LS; Wang HM; Cao WT; Zhang JW; Hu HB; Cai Y; Wang H; Deng YH
    J Surg Oncol; 2021 Dec; 124(8):1442-1450. PubMed ID: 34494280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
    Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
    Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras.
    Cavnar MJ; Seier K; Curtin C; Balachandran VP; Coit DG; Yoon SS; Crago AM; Strong VE; Tap WD; Gönen M; Antonescu CR; Brennan MF; Singer S; DeMatteo RP
    Ann Surg; 2021 Jan; 273(1):128-138. PubMed ID: 30946076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
    Tang S; Yin Y; Shen C; Chen J; Yin X; Zhang B; Yao Y; Yang J; Chen Z
    World J Surg Oncol; 2017 Apr; 15(1):79. PubMed ID: 28399894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
    Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
    Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.
    Call J; Walentas CD; Eickhoff JC; Scherzer N
    BMC Cancer; 2012 Mar; 12():90. PubMed ID: 22429770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?
    Sutton TL; Walker BS; Billingsley KG; Sheppard BC; Corless CL; Heinrich MC; Mayo SC
    Surgery; 2021 Nov; 170(5):1481-1486. PubMed ID: 34090672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.